<DOC>
	<DOCNO>NCT02352974</DOCNO>
	<brief_summary>The objective study - Evaluate safety give GAD-Alum ( Diamyd ) directly lymph gland combination oral vitamin D regimen - Evaluate mention treatment influence immune system endogenous insulin secretion .</brief_summary>
	<brief_title>GAD-Alum ( Diamyd ) Administered Into Lymph Nodes Combination With Vitamin D Type 1 Diabetes ( DIAGNODE-1 )</brief_title>
	<detailed_description>Eligible patient treat 4 µg GAD-Alum inguinal lymph gland three occasion , one month interval combination Vitamin D ( 14 000 IU/week ) 4 month , start 1 month prior first GAD-Alum injection .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Informed consent give patient 2 . Type 1 diabetes accord ADA classification &lt; 6 month diabetes duration 3 . Age 12.0029.99 year diagnosis Type 1 diabetes 4 . Fasting Cpeptide ≥0.12 nmol/L 5 . Pos GADA &lt; 50 000 random unit 6 . Females must agree avoid pregnancy negative urine pregnancy test 7 . Patients childbearing potential must agree use adequate contraception , 1 year last administration GADAlum . 1 . Previous current treatment immunosuppressant therapy ( although topical inhale steroid accept ) 2 . Continuous treatment inflammatory drug ( sporadic treatment e.g . headache connection fever day accept ) 3 . Treatment oral inject antidiabetic medication insulin 4 . Treatment Vitamin D , market , unwilling abstain medication trial 5 . A history anaemia significantly abnormal haematology result screen 6 . A history epilepsy , head trauma cerebrovascular accident , clinical feature continuous motor unit activity proximal muscle 7 . Clinically significant history acute reaction vaccine drug past 8 . Treatment vaccine , include influenza vaccine , within 4 month prior plan first study drug dose plan treatment vaccine 4 month last injection study drug . 9 . Participation clinical trial new chemical entity within previous 3 month 10 . Inability unwillingness comply provision protocol 11 . A history alcohol drug abuse 12 . A significant illness diabetes within 2 week prior first dose 13 . Known human immunodeficiency virus ( HIV ) hepatitis 14 . Females lactate pregnant ( possibility pregnancy must exclude urine βHCG onsite within 24 hour prior GADAlum treatment ) 15 . Males female willing use adequate contraception 1 year last GADAlum treatment 16 . Presence associate serious disease condition , include active skin infection preclude subcutaneous injection , opinion investigator make patient noneligible study 17 . Deemed investigator able follow instruction and/or follow study protocol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diamyd</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Juvenile Diabetes</keyword>
	<keyword>Diabetes Type 1</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Insulin Dependent Diabetes</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>rhGAD65</keyword>
	<keyword>GAD65</keyword>
	<keyword>GAD-Alum</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes mellitus Type 1</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Vitamin D</keyword>
</DOC>